Every 10-Q that Lifecore Biomedical, Inc. (LFCR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LFCR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LFCR filings page.
Lifecore Biomedical generated Q2 2026 revenue of $34.2 million and a net loss of $6.2 million; first‑half revenue was $57.4 million with a $21.1 million net loss. CDMO revenue declined while HA manufacturing grew in the quarter, and gross margin eased to 35.3%.
R&D and SG&A expenses fell year on year, and operating cash flow was positive at $2.5 million, but higher interest expense and losses on a related‑party debt derivative deepened overall losses. Cash was $17.2 million with $21.6 million of revolver availability and $192.7 million outstanding on a term loan from major customer Alcon.
The balance sheet includes $50.2 million of Series A Redeemable Convertible Preferred Stock; all shares have been noticed for redemption in December 2026, which would require lender consents and could accrue extra charges if unpaid. Lifecore reports covenant compliance and believes current liquidity covers at least the next twelve months. A securities class action has a preliminarily approved settlement expected to be covered by insurance, while an investor contract dispute continues with limited remaining claims, and an SEC enforcement inquiry related to a past restatement has been closed with no action.
Lifecore Biomedical reports a weak quarter with revenue of $23,193 (thousands), down 34% from $35,154 (thousands), and a net loss of $14,980 (thousands). Gross margin compressed to 19.2% from 28.0% as HA manufacturing sales fell sharply and CDMO volumes declined.
Operating expenses dropped 52% to $9,134 (thousands) mainly because the prior year included a $6,851 (thousands) loss on asset sales and higher legal and professional fees. However, interest expense and the non‑cash loss from the Alcon debt derivative increased, keeping the company in a sizable loss.
Cash was $20,795 (thousands) with $17,300 (thousands) available on the revolver, while total debt principal reached $200,062 (thousands), including $188,627 (thousands) under the Alcon term loan. Redeemable preferred stock carried a $49,263 (thousands) liquidation preference and can be put to the company for cash redemption starting June 29, 2026.
Lifecore Biomedical (LFCR) reported Q3 results for the calendar quarter ended September 30, 2025. Total revenues were $31,109 thousand, up from $24,705 thousand, driven by HA manufacturing $9,360 thousand and CDMO $21,749 thousand. Gross profit rose to $7,791 thousand from $5,387 thousand, and the operating loss improved to $3,067 thousand from $11,584 thousand.
Net loss was $9,991 thousand versus $16,230 thousand, with loss per share of $0.29. Cash and cash equivalents were $18,856 thousand. The company completed a capacity expansion expected to more than double aseptic capacity; depreciation is expected to increase by approximately $1,600 per year.
Alcon accounted for 38% of revenue and is also the term-loan lender. Related party term-loan principal was $179,562 thousand with an effective annual interest rate of 20.9%, and the company remained in compliance with covenants. Contract liabilities, current, were $7,214 thousand. Shares outstanding were 37,466,352 as of October 30, 2025. The company paid-in-kind preferred dividends of $874 thousand and recorded a stockholders’ equity deficit of $10,537 thousand.